Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.
Greenblatt
D J
DJ
von Moltke
L L
LL
Daily
J P
JP
Harmatz
J S
JS
Shader
R I
RI
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000201:enzymology; D000525:Alprazolam / Q000493:pharmacokinetics*; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000097:blood; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000493:pharmacokinetics*; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D010089:Oxidoreductases, N-Demethylating / Q000037:antagonists & inhibitors* / Q000097:blood; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects*; D014229:Triazolam / Q000493:pharmacokinetics*
D065607:Cytochrome P-450 Enzyme Inhibitors; D017320:HIV Protease Inhibitors; D006993:Hypnotics and Sedatives; D014229:Triazolam; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating; D019438:Ritonavir; D000525:Alprazolam